7 unknown. 7 Phase 2, 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Unknown 7 |
| Phase 3 | 6 | Unknown 6 |
Follow Sofosbuvir: new trials by email Literature Review of Sofosbuvir trials Research Report on Sofosbuvir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sofosbuvir in Treatment of COVID 19 sofosbuvir, Sofosbuvir ledipsavir, Daclatasvir - COVID | Phase 2 / Phase 3 | Unknown | Tanta University | 60 | 2020-08-01 | 2020-12-08 |
| Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients Sofosbuvir, Daclatasvir - Covid19 | Phase 2 / Phase 3 | Unknown | Tanta University | 100 | 2020-07-01 | 2020-12-03 |
| Efficacy and Safety of Anti HCV Drugs in the Treatment of COVID-19 Hydroxychloroquine , Sofosbuvir, daclatasvir, Standard of care treatment - COVID-19 | Phase 2 / Phase 3 | Unknown | Cairo University | 100 | 2020-07-01 | 2020-06-25 |
| Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 2,3,6 Hepatitis C Virus Infection Patients Seraprevir, Sofosbuvir - Hepatitis C Virus Infection | Phase 2 | Unknown | Ginkgopharma CO., LTD | 36 | 2019-04-03 | 2019-10-01 |
| Clinical Pharmacokinetics of Daclatasvir/Sofosbuvir in Adolescents With Hepatitis C Virus Daclatasvir and sofosbuvir - Chronic HCV Infection | Phase 2 / Phase 3 | Unknown | Ain Shams University | 50 | 2017-12-10 | 2023-03-06 |
| Strategic Transformation of the Market of HCV Treatments sofosbuvir + ravidasvir - Hepatitis C | Phase 2 / Phase 3 | Unknown | Drugs for Neglected Diseases | 603 | 2016-09-01 | 2021-01-20 |
| A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4 ravidasvir hydrochloride, sofosbuvir, ribavirin - Chronic Hepatitis C | Phase 2 / Phase 3 | Unknown | Pharco Pharmaceuticals | 300 | 2015-01-01 | 2016-04-07 |
COVID-19 (2) · Hepatitis C (2) · Hepatitis C, Chronic (1)
Tanta University (2) · Ain Shams University (1) · Cairo University (1) · Drugs for Neglected Diseases (1) · Ginkgopharma CO., LTD (1) · Pharco Pharmaceuticals (1)
Egypt (4) · China (1) · Malaysia (1) · Thailand (1)
Ahmed Cordie, lecturer (1) · Gamal Esmat, M.D. (1) · Gamal Esmat, Professor (1) · Isabelle Andrieux-Meyer, MD (1) · Manal H El-Sayed, MD (1) · Marwa Salama, Consultant (1) · Marwa Salama, Lecturer (1) · Satawat Thongsawat, MD (1) · Soek-Siam Tan, MD (1) · Xuegang Wu (1)